Christopher Paul German Sells 344 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German sold 344 shares of the firm’s stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $54.23, for a total transaction of $18,655.12. Following the completion of the transaction, the chief accounting officer now owns 2,889 shares of the company’s stock, valued at approximately $156,670.47. This trade represents a 10.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Christopher Paul German also recently made the following trade(s):

• On Wednesday, February 19th, Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $57.22, for a total transaction of $36,334.70.

Rhythm Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ RYTM opened at $52.91 on Wednesday. The firm has a market cap of $3.35 billion, a PE ratio of -12.22 and a beta of 2.30. The company’s fifty day simple moving average is $55.28 and its 200 day simple moving average is $54.99. Rhythm Pharmaceuticals, Inc. has a 12-month low of $35.17 and a 12-month high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The company had revenue of $41.83 million for the quarter, compared to the consensus estimate of $38.48 million. On average, equities analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Analyst Ratings Changes

RYTM has been the topic of a number of recent research reports. JMP Securities reiterated a “market outperform” rating and set a $75.00 price target on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Stifel Nicolaus began coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They set a “buy” rating and a $78.00 target price on the stock. Oppenheimer started coverage on Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an “outperform” rating and a $76.00 price target on the stock. The Goldman Sachs Group raised their price objective on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $69.46.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Castleark Management LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 1.3% in the 3rd quarter. Castleark Management LLC now owns 19,260 shares of the company’s stock worth $1,009,000 after purchasing an additional 250 shares in the last quarter. Two Sigma Advisers LP raised its holdings in Rhythm Pharmaceuticals by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 13,100 shares of the company’s stock worth $733,000 after buying an additional 300 shares during the last quarter. SRS Capital Advisors Inc. raised its holdings in Rhythm Pharmaceuticals by 740.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after buying an additional 400 shares during the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals in the fourth quarter valued at $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Rhythm Pharmaceuticals by 2.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,156 shares of the company’s stock valued at $1,857,000 after buying an additional 654 shares during the last quarter.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.